Background: Bevacizumab was approved by the FDA for use in the first-line treatment of metastatic colon cancer in February, 2004. Trial results presented at ASCO 2009 suggested that bevacizumab has no ...
Even with Cologuard’s label as an “alternative,” the test is covered by Anthem Blue Cross and Blue Shield and several other insurers, including all health plans in the Madison area. Exact Sciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback